Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 73,995 $ 125,806
Marketable securities 114,564 60,729
Prepaid research and development expenses 1,384 2,371
Other prepaid expenses and current assets 2,103 2,193
Total current assets 192,046 191,099
Property and equipment, net 1,024 1,178
Non-current marketable securities 4,885 8,067
Operating lease right-of-use asset 239 254
Other assets 2,448 1,720
Total assets 200,642 202,318
Current liabilities:    
Accounts payable 199 2,728
Accrued research and development expenses 9,659 9,752
Other accrued liabilities 4,181 5,886
Total current liabilities 14,039 18,366
Development financing liability 78,685 50,320
Long-term portion of operating lease liability 537 695
Total liabilities 93,261 69,381
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 84,677,939 and 84,677,939 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 8 8
Additional paid-in capital 902,217 899,798
Accumulated other comprehensive (loss) income (219) (13)
Accumulated deficit (794,625) (766,856)
Total stockholders' equity 107,381 132,937
Total liabilities and stockholders' equity $ 200,642 $ 202,318